| Ytd | 1.90% | |
| 1y | -46.77% |
| Open | 5.34 | Prev Close | 5.35 | Low | 5.34 | High | 5.35 | Mkt Cap | 7.82M |
| Vol | 1.16K | Avg Vol | 6.40K | EPS | -17.90 | P/E | N/A | Forward P/E | -0.28 |
| Beta | 1.05 | Short Ratio | 0.04 | Inst. Own | 0.79% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-18 | 50-d Avg | 5.48 | 200-d Avg | 4.66 | 1yr Est | 0.50 |
CNSP News
Shares of CNS Pharmaceuticals, Inc. (NASDAQ: CNSP - Get Free Report) traded up 1.5% on Friday. The s
Gainers Can Fite Biopharma (AMEX:CANF) shares moved upwards by 20.4% to $3.96 during Wednesday'
CNS Pharmaceuticals (NASDAQ:CNSP) reported quarterly losses of $(0.38) per share which missed the an
Gainers NextCure (NASDAQ:NXTC) shares rose 305.5% to $8.84 during Tuesday's pre-market session.
Gainers Can Fite Biopharma (AMEX:CANF) stock moved upwards by 52.0% to $4.52 during Wednesday's
CNS Pharmaceuticals (NASDAQ:CNSP) reported quarterly losses of $(7.30) per share which missed the an
CNS Pharmaceuticals plans a pivot to an acquisition-led strategy, capital raise, and technicals sign
US stocks traded lower with Dow down 0.4%. NASDAQ up 0.07% while S&P 500 fell 0.03%. Norwegian C
US stocks fell, Dow dropped 150 points. Dow at 49,321.96, NASDAQ at 25,109.76, S&P 500 at 7,223.
CNS Pharmaceuticals announces $22.5 million financing as the company pivots its strategy, eyes asset
The private placement includes participation from institutional healthcare investors, including ADAR
EBAY: 13% | GameStop's Cohen Threatens Proxy War In High-Stakes eBay Bid CNSP: 165% | CNS Pharma
Newly formed executive team initiates global search for differentiated therapeutic assets for neurol
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001729427/000168316826001066/cns_8k.htm
CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutica
CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutica
CNS Pharmaceuticals (NASDAQ:CNSP) reported quarterly losses of $(5.76) per share which beat the anal
Maxim Group analyst Jason McCarthy upgrades CNS Pharma (NASDAQ:CNSP) from Hold to Buy and announc
CNS Pharmaceuticals (NASDAQ:CNSP) reported quarterly losses of $(6.42) per share which beat the anal
CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutica
CNS Pharmaceuticals (NASDAQ:CNSP) reported quarterly losses of $(1.58) per share which beat the anal
CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutica
COIN: 10% | Coinbase Global shares are trading higher it was announced that the company will join th
CNS Pharmaceuticals' Berubicin trial results show a favorable safety profile with no cardiotoxic
